OCX Stock Overview
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.56 |
| 52 Week High | US$6.20 |
| 52 Week Low | US$2.08 |
| Beta | 0.78 |
| 1 Month Change | -14.67% |
| 3 Month Change | -23.58% |
| 1 Year Change | -53.06% |
| 3 Year Change | -97.11% |
| 5 Year Change | -97.02% |
| Change since IPO | -97.95% |
Recent News & Updates
Recent updates
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?
Jan 25OncoCyte signs an at-the-market agreement to sell $50M of common stock
Jun 14Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt
Jun 02Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like
Mar 18Does OncoCyte (NYSEMKT:OCX) Have A Healthy Balance Sheet?
Jan 27Read This Before Selling OncoCyte Corporation (NYSEMKT:OCX) Shares
Dec 23
Shareholder Returns
| OCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.7% | -4.7% | -3.7% |
| 1Y | -53.1% | -2.7% | 20.2% |
Return vs Industry: OCX underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: OCX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| OCX volatility | |
|---|---|
| OCX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OCX's share price has been volatile over the past 3 months.
Volatility Over Time: OCX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 76 | Josh Riggs | oncocyte.com |
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
OncoCyte Corporation Fundamentals Summary
| OCX fundamental statistics | |
|---|---|
| Market cap | US$21.18m |
| Earnings (TTM) | -US$25.80m |
| Revenue (TTM) | US$1.50m |
14.1x
P/S Ratio-0.8x
P/E RatioIs OCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCX income statement (TTM) | |
|---|---|
| Revenue | US$1.50m |
| Cost of Revenue | US$1.00m |
| Gross Profit | US$501.00k |
| Other Expenses | US$26.30m |
| Earnings | -US$25.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.12 |
| Gross Margin | 33.33% |
| Net Profit Margin | -1,716.37% |
| Debt/Equity Ratio | 0% |
How did OCX perform over the long term?
See historical performance and comparison